Severity index (SI)
The Severity Index (SI) of the study indicates that PSO CARE was effective in reducing the psoriatic effect on the rodents, with the low SI value indicating higher efficacy
Efficacy
Th1 and Th17 cell responses
PSO CARE possesses numerous bioactive molecules that have been shown to reduce inflammation by modulating Th1 and Th17 cell responses and inhibiting pro-inflammatory cytokines.
Psoriasis area and severity index (PASI) scoring of psoriatic skin in Imiquimod-induced normal control (Cont) disease control (DC), standard (STD-Clobetasol Propionate), PSO CARE Low (D1), PSO CARE Intermediate (D2) and PSO CARE High (D3) treated group on day Day 7 and day 14.
Data expressed are mean ± standard deviation (n=3). *P < 0.05 compared to DC vs. PSO CARE at Day 7 &14.
WHAT THIS MEANS TO YOU
01
If you're managing psoriasis, this study shows that PSO CARE effectively reduces symptoms by decreasing the Severity Index (SI). This means that the product has been proven to help reduce inflammation and improve skin health over time.
02
The analysis indicates that PSO CARE enhances antioxidants in the skin, like glutathione (GSH) and superoxide dismutase (SOD), which fight oxidative damage.v
03
For you, this means better skin repair and protection, especially if your skin is prone to inflammation or environmental damage.
Antioxidant Analysis
in tissue sample
Antioxidant analysis of skin tissues across different groups: normal control (Cont), disease control (DC), standard (STD - Clobetasol Propionate), PSO CARE Low (D1), PSO CARE Intermediate (D2), and PSO CARE High (D3) treated groups.
Data were analyzed using one-way ANOVA followed by the post hoc Bonferroni test, with significance levels indicated as ***p < 0.001, **p < 0.01, and *p < 0.05.
ELISA Analysis on tissue sample across different groups: normal control (Cont), disease control (DC), standard (STD - Clobetasol Propionate), PSO CARE Low (D1), PSO CARE Intermediate (D2), and PSO CARE High (D3) treated groups.
Data were analyzed using one-way ANOVA followed by the post hoc Bonferroni test, with significance levels indicated as **** p<0.0001 *** p<0.001, **P<0.01, *P<0.05.
WHAT THIS MEANS TO YOU
01
This analysis measures inflammatory markers in the skin. Results show that PSO CARE lowers key pro-inflammatory proteins (like TNF-α, IL-6, and IL-17) while promoting skin recovery.
02
For you, this suggests that using PSO CARE can significantly reduce skin inflammation, leading to quicker healing and relief from conditions like psoriasis.